Custom service

Peptide-Based Nucleic Acid Delivery Services

Deliver sirna, aso or mrna with peptide carriers and ligands

Turnaround: 5–9 weeksTypical scale: mg-scale construct plus validation reportChemistry options: electrostatic and covalent peptide–NA complexes; GalNAc and tissue-selective ligands; serum-stability test matrix

The service is built around electrostatic and covalent peptide–NA complexes. Depending on the molecule we may move to GalNAc and tissue-selective ligands or serum-stability test matrix to improve stability, loading or yield, and every batch is released with delivery system with knockdown or expression data.

Because Peptide-Based Nucleic Acid Deliverys projects usually feed a downstream assay or preclinical study, we lock the release specification early — purity, identity and functional readouts are agreed at quotation, not discovered at delivery.

Tissue-targeted oligonucleotide delivery research

Non-viral mRNA delivery concepts

GMP nucleic-acid drug product

In-vivo dosing campaigns without a completed in-vitro validation stage

Delivery programmes are released in two layers: chemical (identity, purity, payload loading) and functional (uptake, knockdown or transfection readout in the agreed cell model). Both layers are documented, because a construct that is chemically perfect but functionally silent is a failure.

Service Highlights

  • electrostatic and covalent peptide–NA complexes as the default route, with GalNAc and tissue-selective ligands held as a proven fallback
  • Serum-stability test matrix worked into the design where the application requires it
  • Every delivery construct is validated for uptake or knockdown function, not just characterized chemically
  • Analytical confirmation of every intermediate before the final release
  • Serum-stability and competitive-serum conditions are part of the standard test matrix
  • Delivery system with knockdown or expression data delivered with a complete conjugation or synthesis certificate

How the work runs

  1. Payload & target review

    Payload chemistry, target cell and readout are agreed; Peptide-Based Nucleic Acid Delivery Services concept routes are drafted.

  2. Construct design

    Peptide ligand, linker and presentation are designed; electrostatic and covalent peptide–NA complexes is selected.

  3. Assembly

    The construct is assembled and purified chemically, with payload loading quantified.

  4. Functional validation

    Uptake or knockdown is measured in the target cell model, with GalNAc and tissue-selective ligands controls.

  5. Stability & optimization

    Serum stability and iteration rounds tune the design to the agreed specification.

  6. Release & hand-off

    Delivery system with knockdown or expression data plus the validation report is released with a handling SOP.

Specifications & timeline

Turnaround
5–9 weeks
Typical scale
mg-scale construct plus validation report
Chemistry options
electrostatic and covalent peptide–NA complexes; GalNAc and tissue-selective ligands; serum-stability test matrix
Deliverable
Delivery system with knockdown or expression data
QC package
Chemical QC plus functional uptake/delivery assay data
Shipping
Blue ice, aliquoted, with handling SOP

Related Products

Next step

Tell us the target, we will tell you what is feasible

Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.